1988
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome.
Antin J, Smith B, Holmes W, Rosenthal D. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988, 72: 705-13. PMID: 3042046, DOI: 10.1182/blood.v72.2.705.bloodjournal722705.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnemia, AplasticBlood Cell CountBone MarrowCell DivisionColony-Stimulating FactorsDose-Response Relationship, DrugDrug EvaluationFemaleGranulocyte-Macrophage Colony-Stimulating FactorGrowth SubstancesHumansMaleMiddle AgedMyelodysplastic SyndromesRecombinant ProteinsReticulocytesConceptsPhase I/II studyRecombinant human granulocyte-macrophage colony-stimulating factorAplastic anemiaGranulocyte-macrophage colony-stimulating factorMyelodysplastic syndromeColony-stimulating factorHuman granulocyte-macrophage colony-stimulating factorII studyReticulocyte countErythrocyte transfusion requirementsLow-grade feverMyalgia/arthralgiaMicrograms/m2Four-hour intravenous infusionNumber of eosinophilsGM-CSF therapyImmature myeloid cellsLow back discomfortTransfusion requirementsBlood countIntravenous infusionPlatelet countGranulocyte countMonocyte countPatientsPhase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure.
Antin JH, Smith BR, Holmes W, David RN, Rosenthal S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Institute Mitteilungen 1988, 149-53. PMID: 3071331.Peer-Reviewed Original ResearchConceptsPhase I/II studyMicrograms/m2Bone marrow failureII studyMarrow failureGM-CSFSevere bone marrow failureErythrocyte transfusion requirementsMyalgia/arthralgiaLow-grade feverRecombinant human granulocyte-macrophage colony-stimulating factorGranulocyte-macrophage colony-stimulating factorSevere marrow failureLow back discomfortColony-stimulating factorHuman granulocyte-macrophage colony-stimulating factorRecombinant human GM-CSFGrade feverTransfusion requirementsIntravenous infusionMyelodysplastic syndromePlatelet countAplastic anemiaGranulocyte countMonocyte count
1985
EFFICACY OF A CYCLOPHOSPHAMIDE-PROCARBAZINE-ANTITHYMOCYTE SERUM REGIMEN FOR PREVENTION OF GRAFT REJECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR TRANSFUSED PATIENTS WITH APLASTIC ANEMIA
Smith BR, Guinan EC, Parkman R, Ferrara J, Levey RH, Nathan DG, Rappeport JM. EFFICACY OF A CYCLOPHOSPHAMIDE-PROCARBAZINE-ANTITHYMOCYTE SERUM REGIMEN FOR PREVENTION OF GRAFT REJECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR TRANSFUSED PATIENTS WITH APLASTIC ANEMIA. Transplantation 1985, 39: 671-672. PMID: 3890295, DOI: 10.1097/00007890-198506000-00020.Peer-Reviewed Original Research
1983
Application of bone marrow transplantation in genetic diseases
Rappeport J, Smith B, Parkman R, Rosen F. Application of bone marrow transplantation in genetic diseases. Clinics In Haematology 1983, 12: 755-773. PMID: 6416728, DOI: 10.1016/s0308-2261(83)80009-5.Peer-Reviewed Original ResearchAgranulocytosisAnemia, AplasticAnimalsBone Marrow TransplantationCell SeparationChediak-Higashi SyndromeChildFemaleGenes, MHC Class IIGranulomatous Disease, ChronicHLA AntigensHumansImmunologic Deficiency SyndromesInfantMaleMiceMucopolysaccharidosesOsteopetrosisPhagocyte Bactericidal DysfunctionThalassemiaT-LymphocytesTransplantation, IsogeneicWiskott-Aldrich Syndrome